Daxor Announces the Receipt of a Contract for the Placement of a BVA-100 Blood Volume Analyzer at Lankenau Medical Center
(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 04/28/15 -- Daxor Corporation, (NYSE MKT: DXR) a medical instrumentation and biotechnology company, announced the receipt of a signed contract from Lankenau Medical Center of Wynnewood, Pennsylvania, for the placement of a BVA-100 Blood Volume Analyzer. Lankenau Medical Center is a 331 bed tertiary care, teaching hospital and research institute
Lankenau Medical Center serves southeastern Pennsylvania by offering a wide variety of primary and specialty clinical services, residency and fellowship programs, research programs emphasizing cardiovascular disease, cancer and diabetes. Their Emergency Department is certified by the Joint Commission as a Primary Stroke Center. An FAA certified rooftop helipad is available for medevacs.
Lankenau Medical Center is a founding member of Main Line Health, which is a community-based not-for-profit health system that also includes Bryn Mawr Hospital, Paoli Hospital, Riddle Hospital, Bryn Mawr Rehabilitation Hospital, and Mirmont Treatment Center.
Dr. Christopher Droogan, Medical Director of Heart Failure at Lankenau Medical Center, was quoted as saying the following regarding the upcoming placement of the BVA-100 Blood Volume Analyzer:
"In an effort to effectively diagnose proper volume status in many of our critically ill medical and surgical patients as well as the varied heart failure population in our hospital, we look forward to using the Daxor Blood Volume Analyzer to assist our clinicians in their daily practice of medicine. We hope to eliminate unnecessary blood transfusions and decrease invasive hemodynamic monitors which carry risk. In an effort to reduce early readmission we hope to better appreciate the under-treated acutely decompensated heart failure patient."
Dr. Joseph Feldschuh, a cardiologist and the CEO of Daxor, said: "As patients become more aware of how essential blood volume measurement is, they will better understand the importance of being treated on the basis of direct measurement rather than estimates based on imprecise measures."
The Daxor website provides important additional information to help patients understand the benefit of blood volume measurement and which medical facilities in various states across the country are able to provide this life saving test.
To learn more about Daxor, please visit .
Contact Information:
Daxor Corporation:
Richard Dunn
212-330-8502
(Director of Operations)
David Frankel
212-330-8504
(Chief Financial Officer)
Diane Meegan
212-330-8512
(Investor Relations)
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.04.2015 - 06:30 Uhr
Sprache: Deutsch
News-ID 1354559
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Dentistry
Anmerkungen:
Diese Pressemitteilung wurde bisher 155 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Daxor Announces the Receipt of a Contract for the Placement of a BVA-100 Blood Volume Analyzer at Lankenau Medical Center
"
steht unter der journalistisch-redaktionellen Verantwortung von
Daxor Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
